Physician profile
Fan Zhang
NPI 1659735017
$397,562.98
in general payments reported to CMS, 2019-2025
62 companies · $140K in 2025
The $140K reported for 2025 was more than what 99% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $646 · 2020: $2,039 · 2021: $2,770 · 2022: $6,843 · 2023: $115K · 2024: $131K · 2025: $140K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $280K · Travel and Lodging: $36K · Food and Beverage: $33K · Consulting Fee: $32K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $4,580 · Education: $118.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $279,896.00 |
| Travel and Lodging | $35,512.06 |
| Food and Beverage | $33,104.81 |
| Consulting Fee | $32,054.17 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $4,580.00 |
| Education | $117.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $298,571.63 | 2021-2025 | Ingrezza, Ongentys |
| Abbott Laboratories | $60,154.37 | 2021-2025 | Infinity, Proclaim, Aliniq |
| Medtronic, INC. | $11,657.19 | 2021-2025 | Percept Pc Brainsense, Pipeline |
| Merz Pharmaceuticals, LLC | $11,087.33 | 2021-2025 | Inbrija, Xeomin, Ampyra |
| Abbvie INC. | $3,026.61 | 2021-2025 | Ubrelvy, Qulipta, Botox |
| Boston Scientific Corporation | $2,194.26 | 2020-2025 | General - Dbs |
| Medtronic USA, INC. | $1,157.89 | 2019-2020 | |
| Acadia Pharmaceuticals INC | $1,047.78 | 2020-2025 | Nuplazid, Daybue |
| Acorda Therapeutics, INC | $821.94 | 2022-2024 | Inbrija, Ampyra |
| Lundbeck LLC | $652.78 | 2021-2025 | Vyepti, Rexulti |
| Teva Pharmaceuticals USA, INC. | $636.68 | 2020-2025 | Austedo Xr, Austedo Xr |
| Pfizer INC. | $529.85 | 2023-2025 | |
| Lantheus Medical Imaging, INC. | $466.67 | 2025 | |
| Amneal Pharmaceuticals LLC | $436.35 | 2020-2025 | Ongentys 50mg Capsules 30, Rytary, Crexont |
| Ucb, INC. | $386.02 | 2022-2025 | Briviact, Rystiggo |
Show all 62 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fan Zhang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.